Table 1.
Reasons of sample loss over 9 years by health status, gender, and study area (%)
| Descriptions (for A-Ha) | Urban-follow-up (year 2016) | Rural-follow-up (year 2017) | ||||||
|---|---|---|---|---|---|---|---|---|
| A | D | B, C, E, F, G, H | Total | A | D | B, C, E, F, G, H | Total | |
| Participants studied | ||||||||
| Baseline | 521 | 464 | 231 | 1216 | 342 | 631 | 287 | 1260 |
| Follow-up | 290 (55.7) | 209 (45.0) | 84 (36.4) | 583 (47.9) | 255 (74.6) | 403 (63.9) | 145 (50.5) | 803 (63.7) |
| Sample Loss Total | 231 (44.3) | 255 (55.0) | 147 (63.6) | 633 (52.1) | 87 (25.4) | 228 (36.1) | 142 (49.5) | 457 (36.3) |
| Death | ||||||||
| Male | 87 (16.7) | 95 (20.5) | 49 (21.2) | 231 (19.0) | 49 (14.3) | 114 (18.1) | 54 (18.8) | 217 (17.2) |
| Female | 62 (11.9) | 88 (19.0) | 47 (20.4) | 197 (16.2) | 31 (9.1) | 90 (14.3) | 68 (23.7) | 189 (15.0) |
| Total | 149 (28.6) | 183 (39.4) | 96 (41.6) | 428 (35.2) | 80 (23.4) | 204 (32.3) | 122 (42.5) | 406 (32.2) |
| Migration | ||||||||
| Male | 22 (4.2) | 19 (4.1) | 12 (5.2) | 53 (4.4) | 3 (0.9) | 6 (1.0) | 8 (2.8) | 17 (1.4) |
| Female | 31 (6.0) | 26 (5.6) | 21 (9.1) | 78 (6.4) | 4 (1.2) | 18 (2.9) | 12 (4.2) | 34 (2.7) |
| Total | 53 (10.2) | 45 (9.7) | 33 (14.3) | 131 (10.8) | 7 (2.1) | 24 (3.8) | 20 (7.0) | 51 (4.1) |
| Consent withdrew | ||||||||
| Male | 14 (2.7) | 13 (2.8) | 7 (3.0) | 34 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Female | 15 (2.9) | 14 (3.0) | 11 (4.8) | 40 (3.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Total | 29 (5.6) | 27 (5.8) | 18 (7.8) | 74 (6.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
aA – Normal group (participants without discernable abnormality on physical, NP, or cognitive status); B – NP group-NP (participants having diagnosable NP disorders only other than cognitive disorders); C – Cognitive disorder group (participants having diagnosable organic disorders only); D – participants with any physical illness only; E – B+C; F – B+D; G – C+D; H – B+C + D. NP – Neuropsychiatric